Skip to main content
Shionogi & Co.,Ltd. logo

Shionogi & Co.,Ltd. — Investor Relations & Filings

Ticker · 4507 ISIN · JP3347200002 LEI · 35380049VXDTHZI3DY35 T Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2025-05-08 M&A Activity
Country JP Japan
Listing T 4507

About Shionogi & Co.,Ltd.

https://www.shionogi.com/global/en/

Shionogi & Co., Ltd. is a drug discovery-based pharmaceutical company that researches, develops, manufactures, and markets a portfolio of prescription drugs, over-the-counter (OTC) products, and diagnostic reagents. The company prioritizes addressing unmet medical needs, with a significant focus on infectious diseases, including antibiotics, HIV, influenza, and COVID-19. A key strategic area is the development of solutions to combat antimicrobial resistance (AMR). Historically, the company is known for the development of Crestor, a widely used statin. Shionogi aims to provide innovative products and services to improve global health outcomes.

Recent filings

Filing Released Lang Actions
公開買付届出書
M&A Activity Classification · 100% confidence The document is titled with Japanese characters that translate to 'Tender Offer Registration Statement' (公開買付届出書) in the header section. It explicitly mentions '公開買付者' (Tender Offeror: Shionogi & Co., Ltd.) and '対象者' (Target: Torii Pharmaceutical Co., Ltd.). The content details the intent to acquire all shares of the target company through a tender offer (公開買付け) as part of a larger transaction structure involving a subsequent merger (株式併合) and share acquisition (自己株式取得) to take the target private. This structure is characteristic of a mandatory filing related to a takeover bid or tender offer in Japan. The closest matching category is 'Transaction in Own Shares' (POS) or potentially 'Capital/Financing Update' (CAP), but the primary nature is the public offer to acquire shares, which aligns best with the concept of a takeover/tender offer. Given the provided definitions, 'TAR' (M&A Activity) is the most appropriate fit for a document detailing a tender offer aimed at acquiring a target company, even though the specific Japanese form is a 'Tender Offer Registration Statement'.
2025-05-08 Japanese
臨時報告書
M&A Activity Classification · 100% confidence The document is titled with Japanese headers indicating it is a '臨時報告書' (Extraordinary Report or Timely Disclosure Report) submitted to the Kanto Local Finance Bureau ('関東財務局長') on May 7, 2025. The content details a resolution by the Board of Directors of Shionogi & Co., Ltd. regarding a corporate reorganization: an absorption-type company split ('会社分割（簡易吸収分割）') where Shionogi will acquire the pharmaceutical business ('JT医薬事業') from Japan Tobacco Inc. (JT). This type of material disclosure, mandated by Japanese financial regulations (specifically referencing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related Cabinet Office Ordinance), is a significant corporate event disclosure that is not a standard periodic report (like 10-K or IR). In the context of the provided definitions, this highly specific regulatory filing concerning a major corporate transaction (M&A/restructuring) that is not explicitly covered by other codes (like TAR for M&A proposals, which this is past, or CAP for financing) fits best under the general regulatory filing category, or potentially a specific transaction report if one existed. Given the structure and the explicit mention of '臨時報告書' (Timely Disclosure Report), it aligns most closely with a general regulatory filing that doesn't fit the specific definitions like ER, IR, or 10-K. Since it is a formal, mandatory disclosure of a major corporate action (absorption split), and 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' RNS is the most appropriate classification here, as it is a specific type of timely regulatory filing in the Japanese context.
2025-05-07 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 160
2024-11-08 Japanese
半期報告書－第160期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and corporate information for the interim period ending September 30, 2024. This corresponds to the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2024-11-08 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director ('関東財務局長'). The '提出理由' (Reason for Submission) explicitly states that the report is filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the Annual General Meeting ('定時株主総会') held on June 20, 2024. The content details the resolutions passed, including dividend approval (剰余金処分の件) and the election of directors and auditors, along with the voting results (賛成, 反対, 棄権). This structure—a formal filing announcing the results of an AGM—is characteristic of a Declaration of Voting Results & Voting Rights Announcement (DVA). It is not the AGM presentation itself (AGM-R), nor is it a comprehensive annual report (10-K) or a quarterly report (IR). Since it specifically reports the voting outcomes of a general meeting, DVA is the most precise classification.
2024-06-21 Japanese
内部統制報告書－第159期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document header explicitly states the filing type as "【提出書類】 内部統制報告書" (Internal Control Report) and cites the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). This type of report, which assesses the effectiveness of internal controls over financial reporting, is typically filed annually alongside the 10-K, but when presented as a standalone document focusing solely on internal controls assessment, it aligns best with the Audit Report/Information category (AR) or potentially a specific regulatory filing. However, given the specific nature of the content—an assessment of internal controls based on established frameworks and a conclusion on effectiveness as of the fiscal year-end (March 31, 2024)—it is a formal audit/assurance-related document. Since 'AR' is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports)', this classification fits well as it is a formal report on internal control effectiveness, which is a key component of the annual audit process, but is not the full 10-K or a general earnings release. The document is comprehensive, not a short announcement, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule.
2024-06-21 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.